18. Europäische Aids Konferenz
London, Oktober 2021
Die EACS Tagung findet in London und virtuell statt. Unter dem Motto „Crossing Borders“ werden alle relevanten Aspekte rund um HIV angesprochen. Die Studien zu neuen Medikamenten und die Aktualisierung der europäischen Leitlinien sind die Highlights der Konferenz.
https://eacs-conference2021.com/
Mehrklassenresistenz: Fostemsavir oder Ibalizumab?
Die beiden Substanzen sind zugelassen zur Behandlung von HIV-Positiven mit Multiresistenz und Therapieversagen. 
PrEP
In England durch PrEP 87% weniger HIV-Infektionen
EACS 2021 Publikationen Gilead Sciences
EACS-2021-----Gilead-Abstracts.pdf
Acosta_In-vitro-forgivesness-INSTI-regimens_EACS-2021_PE2-68.pptx
Andreatta_1878-BVY-switch-w-preexisiting-resistance-and-blips_EACS-2021_PE1-19.pptx
Andreatta_BVY-switch-pooled-analysis-w-preexisiting-TAMs_EACS-2021_PE1-6.pptx
Brunetta_BICSTAR-PRO-12-mo-data_EACS-2021_PE2-50.pdf
Chastek_Optum_Switch-to-MTR-or-STR-characteristics-patters-VL_EACS-2021_PE2-33.pptx
Feng_NRTI-TAF-TDF-FTC-and-SARS-CoV-2_EACS-2021_PE1-2.pdf
Grebe_Recency-Assays-Simulation_EACS-2021_Poster-PE6-19.pdf
Mallolas_BICSTAR-12-mo-efficacy-safety-persistency_EACS-2021_PE2-57.pdf
Margot_CAPELLA-LEN-resistance-analysis-24-wk-in-HTE_EACS-2021_OS1-1.pptx
Massey_Zero-Transmission-of-HIV-in-MSM-UK-Model_EACS2021_BPD2-1.pptx
Mezzio_Medicaid-Persistence-TN-STR-vs-MTR_EACS-2021-PE7-28.pptx
Patterson_Guidelines-for-the-Assessment-and-Monitoring-of-Comorbidities-in-PLHIV_EACS2021_PE5-34.pdf
Pozniak_1489-1-490-OLE-analysis-in-switch-from-DTG-based-regimens-to-BVY_EACS-20201_PE2-68.pptx
Serrano-Villar_IL-6-clinical-impact_EACS-2021_PE2-34.pptx
Stellbrink_CAPELLA-LEN-in-HTE-subgroup-efficacy-analysis_EACS-2021_PE2-69.pptx
Vendrame_VES-mathematical-model-to-identify-immune-biomarkers_EACS-2021_PE2-1.pptx
Williams_Analysis-of-PRO-tailoring-to-needs-of-PLWH_EACS-2021_PE2-45.pptx
EACS 2021 Publikationen ViiV
|
DOLUTEGRAVIR |
|
|---|---|
|
Switching to DTG/3TC is Non-inferior to Continuing Current Antiretroviral Regiment at
Week 48: SALSA Subgroup Analyses |
|
|
Evaluating the Relationship Between Inflammation Biomarker Interleukin-6 (IL-6)
Levels and Residual, Low-Level Viraemia in HIV-1 Suppressed Participants in the TANGO Study at Week 96 |
|
|
Switching to DTG/3TC is Non-inferior to Continuing a TAF-Based Regimen at Week 144:
TANGO Subgroup Analyses |
|
|
Impact of Treatment Adherence on Efficacy of DTG + 3TC and DTG + TDF/FTC: Pooled Week
144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies |
|
|
12-month outcomes of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and
pre-treated people living with HIV in Germany: Real-world data from the German URBAN cohort |
|
|
Two-year Outcomes of Dolutegravir/Rilpivirine in Virologically Suppressed
HIV-infected PLHIV: Real-world Data from the German JUNGLE Cohort |
|
|
Durable Efficacy and Safety of DTG + 3TC in Treatment-Naive People With HIV-1
Stratified by Age: 144-Week Results From GEMINI-1 and -2 |
|
|
Incidence of hypertension in PLWH receiving InSTI versus other third drug ART
regimens in the RESPOND cohort |
|
|
Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse
Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study |
|
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and
Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB+RPV LA): Interim
Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) |
|
|
Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through
Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies |
|
|
Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir
and Rilpivirine Long-Acting Trials |
|
|
Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL):
Examining Health Care Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir +
Rilpivirine Long-Acting Injectable (CAB+RPV LA) for People Living With HIV |
|
|
Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment:
Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) |
|
|
European Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine:
Efficacy, Safety, and Virologic Outcomes |
|
|
Indirect Comparison of 96-Week Efficacy and Safety of Cabotegravir + Rilpivirine
Long-Acting Every 2 Months Versus Dolutegravir/Abacavir/Lamivudine in Suppressed HIV-1 Infected Participants |
|
|
Outcomes for Participants During Long-term Follow-up After Discontinuation of
Cabotegravir + Rilpivirine Long-Acting in the Phase III/IIIb Clinical Trials |
|
|
FOSTEMSAVIR |
|
|
Comparative Efficacy of Fostemsavir Versus Ibalizumab in Heavily
Treatment-Experienced HIV Patients |
|
|
Long-term Inflammation Biomarker Changes With Fostemsavir in Heavily
Treatment-Experienced Adults With HIV-1: Exploratory Analyses of the Phase 3 BRIGHTE Study |
|
|
Emergent Resistance to Antiretroviral Agents Used in Optimized Background Therapy
With Fostemsavir (FTR): Week 96 Results of the Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living With
Multidrug-Resistant HIV-1 |
|
|
ABACAVIR |
|
|
Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated
People Living with HIV within the RESPOND Cohort Consortium |
|
|
PLHIV PERSPECTIVES |
|
|
Understanding the Perceived Therapeutic Need and Value Associated With Novel
Long-Acting Antiretroviral Regimens Among People Living With HIV in 12 European Countries |
|
Kollegen Fragen
